Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 30 articles:
HTML format
Text format



Single Articles


    June 2018

  1. Corrigendum to "Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer".
    J Natl Cancer Inst. 2018 Jun 28. pii: 5046631. doi: 10.1093.
    PubMed     Text format    


    May 2018
  2. YEUNG TL, Sheng J, Leung CS, Li F, et al
    Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
    J Natl Cancer Inst. 2018 May 31. pii: 5026201. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. TRABERT B, Poole EM, White E, Visvanathan K, et al
    Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
    J Natl Cancer Inst. 2018 May 31. pii: 5026198. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. TRABERT B, Waterboer T, Idahl A, Brenner N, et al
    Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.
    J Natl Cancer Inst. 2018 May 21. pii: 5001107. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  5. CRAMER DW, Elias KM
    Perspectives on Ovarian Cancer From SEER: Today and Tomorrow.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990609. doi: 10.1093.
    PubMed     Text format    


  6. PERES LC, Cushing-Haugen KL, Kobel M, Harris HR, et al
    Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990606. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  7. HILLMAN RT, Chisholm GB, Lu KH, Futreal PA, et al
    Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  8. VISVANATHAN K, Wang TL, Shih IM
    Precancerous Lesions of Ovarian Cancer-A US Perspective.
    J Natl Cancer Inst. 2017 Dec 21. pii: 4769851. doi: 10.1093.
    PubMed     Text format    


    November 2017
  9. FERRARA N
    Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  10. BAIS C, Mueller B, Brady MF, Mannel RS, et al
    Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  11. DOHERTY JA, Jensen A, Kelemen LE, Pearce CL, et al
    Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    August 2017
  12. SCHMIDT MK, van den Broek AJ, Tollenaar RA, Smit VT, et al
    Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    July 2017
  13. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  14. PREVIS RA, Armaiz-Pena GN, Ivan C, Dalton HJ, et al
    Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    March 2017
  15. BRASKY TM, Felix AS, Cohn DE, McMeekin DS, et al
    Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
    J Natl Cancer Inst. 2017;109:1-10.
    PubMed     Text format     Abstract available


    October 2016
  16. FILLON M
    New Guidelines for Treating Ovarian Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    June 2016
  17. DIZON DS, Birrer MJ
    Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus.
    J Natl Cancer Inst. 2016;108:djv442.
    PubMed     Text format     Abstract available


  18. ANGLESIO MS, Wang YK, Maassen M, Horlings HM, et al
    Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality.
    J Natl Cancer Inst. 2016;108:djv428.
    PubMed     Text format     Abstract available


  19. SCHULTHEIS AM, Ng CK, De Filippo MR, Piscuoglio S, et al
    Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
    J Natl Cancer Inst. 2016;108:djv427.
    PubMed     Text format     Abstract available


  20. ZAND B, Previs RA, Zacharias NM, Rupaimoole R, et al
    Role of Increased n-acetylaspartate Levels in Cancer.
    J Natl Cancer Inst. 2016;108:djv426.
    PubMed     Text format     Abstract available


    March 2016
  21. PHAROAH PD, Song H, Dicks E, Intermaggio MP, et al
    PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  22. GOBBO J, Marcion G, Cordonnier M, Dias AM, et al
    Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    February 2016
  23. MEEKS HD, Song H, Michailidou K, Bolla MK, et al
    BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.
    J Natl Cancer Inst. 2015;108.
    PubMed     Text format     Abstract available


    November 2015
  24. BALMANA J, Domchek SM
    BRIP1 as an ovarian cancer susceptibility gene: ready for the clinic?
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format    


  25. RAMUS SJ, Song H, Dicks E, Tyrer JP, et al
    Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format     Abstract available


  26. WALKER CJ, Miranda MA, O'Hern MJ, McElroy JP, et al
    Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format     Abstract available


  27. HUNG RJ, Ulrich CM, Goode EL, Brhane Y, et al
    Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format     Abstract available


    September 2015
  28. DE LA FUENTE A, Alonso-Alconada L, Costa C, Cueva J, et al
    M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis.
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format     Abstract available


    July 2015
  29. WIEMER EA, Berns EM
    MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response.
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format    


  30. LIU G, Yang D, Rupaimoole R, Pecot CV, et al
    Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
    J Natl Cancer Inst. 2015;107.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: